SCHEMBL5776659

SCHEMBL5776659

O=Cc1nc(CCNC(=O)O)cs1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.48
SMN1; SMN2 Q16637 5/20 0.45
NPC1 O15118 1/20 0.45
ALDH1A1 P00352 1/20 0.45
RAB9A P51151 1/20 0.45
GAA P10253 1/20 0.43
HTT P42858 1/20 0.43
HDAC1 Q13547 5/20 0.43
HDAC6 Q9UBN7 5/20 0.43
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC9 Q9UKV0 1/20 0.41
HDAC5 Q9UQL6 1/20 0.41
NCOR2 Q9Y618 1/20 0.41
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6489194 0.79 MAPT (0.71) MAPTSMN1; SMN2NPC1ALDH1A1RAB9A
SCHEMBL28878912 0.73 HDAC1 (0.36) MAPTRAB9AGAAHTTHDAC1
SCHEMBL17261500 0.73 HSD17B10 (0.70) MAPTSMN1; SMN2ALDH1A1RAB9AHSD17B10
SCHEMBL19718385 0.72
SCHEMBL5776654 0.69 NPC1 (0.36) SMN1; SMN2NPC1RAB9AHDAC1HDAC6
SCHEMBL854990 0.69
SCHEMBL20557467 0.68 CDK5 (0.34) MAPTNPC1ALDH1A1RAB9AHDAC1
SCHEMBL4871513 0.68 NOS1 (0.61) MAPTSMN1; SMN2NPC1ALDH1A1RAB9A
SCHEMBL6503635 0.67 PI4KB (0.47) MAPTSMN1; SMN2NPC1ALDH1A1RAB9A
SCHEMBL6679224 0.67 NPC1 (0.42) MAPTSMN1; SMN2NPC1ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060276433-A1 Hydrazone derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-12-07 US disclosed
EP-1612204-A1 HYDRAZONE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-01-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276433-A1 Hydrazone derivative APP, PRNP, HTT MAPT 94/4885SMN1; SMN2 2146/4885NPC1 952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.